November 19, 2008
November 18, 2008
November 17, 2008
November 16, 2008
November 15, 2008
November 14, 2008
November 13, 2008
November 12, 2008
November 16, 2008 – November 22, 2008
November 9, 2008 – November 15, 2008
November 2, 2008 – November 8, 2008
October 26, 2008 – November 1, 2008
October 19, 2008 – October 25, 2008
October 12, 2008 – October 18, 2008
October 5, 2008 – October 11, 2008
September 28, 2008 – October Read the rest of this entry »
’s new drug application for its 80 milligram dose of toremifene, a treatment for the prevention of bone fractures for some men with prostate cancer.
GTx expects to hear within several weeks whether the FDA will give its application a priority or standard review. A priority review would give the product a faster track to market.
The drug would be marketed to men with prostate cancer on androgen deprivation therapy. ADT works by reducing testosterone Read the rest of this entry »
Jan 20, 2009 (Datamonitor via COMTEX) –
— ChemGenex Pharmaceuticals, a developer of personalized oncology medicines, has announced that the FDA has granted orphan drug designation to omacetaxine for the treatment of myelodysplastic syndromes.
Omacetaxine mepesuccinate is a first-in-class cetaxine with established clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces Read the rest of this entry »
Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth – a process called angiogenesis – was by creating drugs aimed at stopping a key vessel growth-promoting protein. But now the opposite seems to be true.
Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla have found evidence that blocking that protein target, called VEGF, or vascular endothelial growth Read the rest of this entry »
A potent substance used in spine-repair surgery to promote bone growth has been linked to life-threatening complications in dozens of patients.
Many of the complications involving the product, Medtronic Inc.’s Infuse Bone Graft, have occurred during “off label” uses, when surgeons use it in ways that haven’t been approved by the Food and Drug Administration.
The FDA warned surgeons in July that it had received reports of life-threatening complications Read the rest of this entry »
It’s February, and the number on the scale is not going down. Frustration sets in. For some dieters, it means turning to more drastic measures to lose weight —- like fasting, celebrity-style.
Celebrities who fast on occasion include singer Beyonce and actors Ben Affleck and Gwyneth Paltrow. Beyonce said she lost 20 pounds by fasting (and sipping a concoction of water, maple syrup, lemon juice and cayenne pepper) for her role in the film Read the rest of this entry »
WASHINGTON — Rep. Pete Stark, chairman of the House Ways and Means Committee’s health panel, will be an important player as Washington tackles health care next year. But his blunt criticism of opponents and his positions to the left of many other Democrats promise to make the process bumpier.
The California Democrat delivered his latest zinger last week, saying he wouldn’t negotiate with insurance companies on a health-care overhaul. “I think their Read the rest of this entry »
October 14, 2008 22:40:00
Tasmanian politicians and interest groups have faced a barrage of questions over plans to build a new hospital at the Hobart railyards.
About 300 people attended a public forum regarding the hospital at a meeting at the Hobart Town Hall this evening.
The forum was coordinated by the Hobart City Council to give people a chance to question a panel of the project’s stakeholders.
Representatives from TasPorts, the Retail Read the rest of this entry »
Wellpoint, the nation’s largest health insurance company, has agreed to pay $10 million and to change how it sets reimbursement rates to avoid civil litigation over price-fixing with
State, Attorney General Andrew Cuomo said Wednesday.
Wellpoint and its subsidiary, Empire Blue Cross Blue Shield, the largest medical insurer in New York with five-million customers, are the latest in a string of national insurance companies to settle with Cuomo’s Read the rest of this entry »
Solvay Pharmaceuticals, Inc. Offers New Tools for the New Year to Help Women
Identify and Discuss Symptoms of Low Testosterone in their Husbands and Male
Partners
MARIETTA, Ga., Jan. 5 /PRNewswire-FirstCall/ — Nine out of 10 women in
the United States are unaware that if their husband or male partner
experiences symptoms like fatigue, depressed mood and increased waistline it
could be related to a condition known as low testosterone, or Low T, according
to Read the rest of this entry »